Lactobacillus sakei ADM14 Induces Anti-Obesity Effects and Changes in Gut Microbiome in High-Fat Diet-Induced Obese Mice

Abstract

The aim of our study was to evaluate the anti-obesity effects of Lactobacillus sakei (L. sakei) ADM14 administration in a high-fat diet-induced obese mouse model and the resulting changes in the intestinal microbiota. Prior to in vivo testing, L. sakei ADM14 was shown to inhibit adipogenesis through in vitro test and genetic analysis. Subsequently, mice were orally administered 0.85% saline supplemented or not with L. sakei ADM14 to high-fat diet group and normal diet group daily. The results showed that administration of L. sakei ADM14 reduced weight gain, epididymal fat expansion, and total blood cholesterol and glucose levels, and significantly decreased expression of lipid-related genes in the epididymal fat pad. Administration of L. sakei ADM14 showed improvement in terms of energy harvesting while restoring the Firmicutes to Bacteroidetes ratio and also increased the relative abundance of specific microbial taxa such as Bacteroides faecichinchillae and Alistipes, which are abundant in non-obese people. L. sakei ADM14 affected the modulation of gut microbiota, altered the strain profile of short-chain fatty acid production in the cecum and enhanced the stimulation of butyrate production. Overall, L. sakei ADM14 showed potential as a therapeutic probiotic supplement for metabolic disorders, confirming the positive changes of in vivo indicators and controlling gut microbiota in a high-fat diet-induced obese mouse model.

Oral Administration of Latilactobacillus sakei ADM14 Improves Lipid Metabolism and Fecal Microbiota Profile Associated With Metabolic Dysfunction in a High-Fat Diet Mouse Model

“…Although, there is no significant difference in total caloric consumption, the difference in physical indicators is confirmed to be an inhibitory effect by L. sakei ADM14 (Figure 1). The reduction in the weight of subcutaneous fat tissue, as well as reduction in the weight of the epididymal fat tissue also observed previous study (Won et al, 2020b), appears to induce the overall decrease in lipid accumulation in mice administered with L. sakei AMD14. In this study, it was found that the weight of the liver was decreased, and as a result of microscopic observation through Oil Red O staining of the liver tissue, a decrease in the size of the adipocytes was observed (Figures 1D,E).…”

“…The HD group showed a steady increase in the Proteobacteria ratios, but the HDA group decreased again from 6 to 10 weeks in the Proteobacteria ratios. The proportions of the three major phyla, Firmicutes, Bacteroidetes, and Proteobacteria, at 10 weeks of HD and HDA groups were similar with those of the two groups shown in cecal microbiota from our previous study (Won et al, 2020b), even though the proportion of the Proteobacteria in HDA group is higher than that of Bacteroidetes in the study of Won et al (2020b). However, the Verrucomicrobia, which was the second major phylum in the cecal microbiota of HD group, was found only as minor phylum at 6 and 10 weeks in fecal microbiota of this study (Won et al, 2020b; Figure 4A).…”

“…Animal studies and clinical studies have reported the anti-obesity effects of probiotic lactic acid bacteria and improvements in metabolic disorders (Dahiya et al, 2017). In this study, the administration of L. sakei AMD14 suppressed weight gain and reduced body fat mass in a high-fat mouse model as shown in our previous study (Won et al, 2020b). Although, there is no significant difference in total caloric consumption, the difference in physical indicators is confirmed to be an inhibitory effect by L. sakei ADM14 (Figure 1).…”

Therapeutic and Improving Function of Lactobacilli in the Prevention and Treatment of Cardiovascular-Related Diseases: A Novel Perspective From Gut Microbiota

“…L. sakei OK67 ameliorated HFD-induced blood glucose intolerance and obesity in mice by reducing inflammation and increasing the expression of colon tight junction proteins in mice ( 12 , 197 ). Various obesity-associated biomarkers in the GM were also beneficially influenced by L. sakei administration ( 198 , 199 ). L. salivarius Ls-33 modified fecal microbiota by increasing the Bacteroides–Prevotella–Porphyromonas group/Firmicutes ratio in obese adolescents ( 47 ).…”

Integrated Phenotypic-Genotypic Analysis of Latilactobacillus sakei from Different Niches

“…In addition, L. sakei is used as a starter for fermented meat products [11] and kimchi [12] in the food industry, ensuring product quality and accelerates the fermentation rate. It is worth noting that L. sakei also has a variety of probiotic functions, such as regulating immunity [13], improving metabolic syndrome [14] and relieving inflammatory diseases [15]. In recent years, some studies have shown that L. sakei can reduce the expression of pro-inflammatory cytokines related to psoriasis and improve the severity of psoriasis in mice [16].…”